Some studies have confirmed that the progression of ovarian cancer disease is the result of multiple mechanisms, the most important of which is angiogenesis, a complex pathological and physiological process regulated by a larger number of positive and negative regulators, while vascular endothelial cell growth factor (VEGF) is the most specific and effective one, thus inhibiting VEGF may decrease angiogenesis and slow the progression of disease in ovarian cancer patients. Here, VEGFA is linked to ovarian cancer.